As of 2026, Mounjaro (tirzepatide) is an established once-weekly injection in the UK for adults with obesity, or overweight with a weight-related comorbidity, used alongside a reduced-calorie diet and increased physical activity. It targets GLP-1 and GIP receptors to help reduce appetite and support weight loss, with dosing increased in clear steps under clinical supervision.

UK prescribers and patients now have substantial real-world experience with titration, injection technique, missed-dose rules, and follow-up, alongside the SURPASS trial programme that supported licensing. Dose escalation and monitoring are a routine part of obesity care rather than an experimental phase.
Mounjaro remains one of the most effective licensed options in its class when used as part of a broader plan. The table below summarises the standard month-by-month titration many new starters are guided through in practice, up to the 15 mg maximum weekly maintenance dose when appropriate.
